Alzheimer's Disease Partnering - 2009-2014

Published: February 2014 | Pages: 100+

Alzheimer's Disease Partnering 2009-2014 report provides understanding and access to the alzheimer's disease partnering deals and agreements entered into by the worlds leading healthcare companies. 


  • Trends in alzheimer's disease partnering deals
  • Top alzheimer's disease deals by value
  • Deals listed by company A-Z, industry sector, stage of development, technology type

The Alzheimer’s Disease Partnering 2009-2014 provides understanding and access to the alzheimer’s disease partnering deals and agreements entered into by the worlds leading healthcare companies.


The report provides an analysis of alzheimer’s disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors alzheimer’s disease technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.


Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.


This data driven report contains over 190 links to online copies of actual alzheimer’s disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.


The initial chapters of this report provide an orientation of alzheimer’s disease partnering trends.


Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in alzheimer’s disease partnering since 2009, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.


Chapter 3 provides an overview of the leading alzheimer’s disease deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.


Chapter 4 provides a comprehensive directory of alzheimer’s disease partnering deals signed and announced since 2009. Thechapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the
research, development and commercialization of dementia technologies and products.


Report scope 


Alzheimer’s Disease Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to alzheimer’s disease trends and structure of deals entered into by leading companies worldwide.


This data driven report includes:


  • Trends in alzheimer’s disease dealmaking in the biopharma industry since 2009
  • Access to summary headline, upfront, milestone and royalty data
  • The leading dementia deals by value since 2009

In Alzheimer’s Disease Partnering 2009-2014, the available deals are listed by:


  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Company A-Z
  • Industry sector
  • Stage of development at signing
  • Deal component type
  • Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Executive Summary 


Chapter 1 – Introduction 


Chapter 2 – Trends in alzheimer's disease partnering 


  • 2.1. Introduction
  • 2.2. Alzheimer's disease partnering over the years
  • 2.3. Bigpharma alzheimer's disease dealmaking activity
  • 2.4. Alzheimer's disease partnering by deal type
  • 2.5. Alzheimer's disease partnering industry sector
  • 2.6. Alzheimer's disease partnering by stage of development
  • 2.7. Alzheimer's disease partnering by technology type
  • 2.8. Disclosed financial deal terms for alzheimer's disease partnering
  • 2.8.1 Alzheimer's disease headline values
  • 2.8.2 Alzheimer's disease upfront payments
  • 2.8.3 Alzheimer's disease milestone payments
  • 2.8.4 Alzheimer's disease royalty rates

Chapter 3 – Leading alzheimer's disease deals 


  • 3.1. Introduction
  • 3.2. Top alzheimer's disease deals by value
  • 3.3. Top alzheimer's disease deals involving bigpharma

Chapter 4 – Dealmaking directory 


  • 4.1. Introduction
  • 4.2. Company A-Z
  • 4.3. By deal type
  • Asset purchase
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Contract service
  • Co-promotion
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Termination
  • 4.4. By industry sector
  • Academic
  • Bigpharma
  • Biotech
  • Drug delivery
  • Medical device
  • Diagnostic
  • Generic pharma
  • Government
  • Non-profit
  • Pharmaceutical
  • Research tools
  • Services
  • Specialty pharma
  • 4.5. By stage of development
  • Discovery
  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Registration
  • Marketed
  • 4.6. By technology type
  • Analysis
  • Animal models
  • Assays
  • Bioinformatics
  • Biological compounds
  • Biomarkers
  • Biomaterials
  • Cell culture
  • Cell therapy
  • Clinical testing
  • Diagnostic - companion
  • Devices
  • Diagnostics
  • Discovery tools
  • DNA probes
  • Drug delivery
  • Enabling technology
  • Epigenetics
  • Equipment
  • Facilities
  • Gene therapy
  • Genomics
  • Imaging
  • Industrial chemicals
  • In vitro models
  • Monoclonal antibodies
  • Nanotechnology
  • Oligonucleotide
  • Peptides
  • Personalised medicine
  • Processes
  • Proteomics
  • Radio/Chemo-therapy
  • Recombinant DNA
  • Research services
  • Research supplies
  • RNA therapeutics
  • Screening
  • Small molecules
  • Stem cells
  • Vaccines

Chapter 5 – Partnering resource center 


  • 5.1. Online partnering
  • 5.2. Partnering events
  • 5.3. Further reading on dealmaking



  • Appendix 1 – Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent titles from CurrentPartnering
  • Order Form – Reports

Table of figures 


  • Figure 1: Alzheimer's disease partnering since 2009
  • Figure 2: Bigpharma – top 50 –alzheimer's disease deals 2009 to 2014
  • Figure 3: Bigpharma alzheimer's disease deal frequency – 2009 to 2014
  • Figure 4: Alzheimer's disease partnering by deal type since 2009
  • Figure 5: Alzheimer's disease partnering by industry sector since 2009
  • Figure 6: Alzheimer's disease partnering by stage of development since 2009
  • Figure 7: Alzheimer's disease partnering by technology type since 2009
  • Figure 8: Alzheimer's disease deals with a headline value
  • Figure 9: Alzheimer's disease deals with upfront payment values
  • Figure 10: Alzheimer's disease deals with milestone payments
  • Figure 11: Alzheimer's disease deals with royalty rates, %
  • Figure 12: Top alzheimer's disease deals by value since 2009
  • Figure 13: Top alzheimer's disease deals signed by bigpharma value since 2009
  • Figure 14: Online partnering resources
  • Figure 15: Forthcoming partnering events
  • Figure 16: Deal type definitions